Literature DB >> 28190705

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.

Lamiae Grimaldi-Bensouda1, Michel Rossignol2, Isabelle Koné-Paut3, Alain Krivitzky4, Christine Lebrun-Frenay5, Johanna Clet6, David Brassat7, Caroline Papeix8, Marc Nicolino9, Pierre-Yves Benhamou10, Olivier Fain11, Nathalie Costedoat-Chalumeau12, Marie-France Courcoux13, Jean-François Viallard14, Bertrand Godeau15, Thomas Papo16, Patrick Vermersch17, Isabelle Bourgault-Villada18, Gerard Breart19, Lucien Abenhaim20.   

Abstract

BACKGROUND: Safety of HPV vaccines is still in question due to reports of autoimmune diseases (ADs) following HPV immunization.
OBJECTIVES: To assess the risk of ADs associated with HPV vaccination of female adolescents/young adults in France.
METHODS: Systematic prospective case-referent study conducted to assess the risks associated with real-life use of HPV vaccines. Cases were female 11-25 years old with incident ADs [central demyelination/multiple sclerosis (CD/MS), connective tissue disease (CTD), Guillain-Barré syndrome (GBS), type-1 diabetes (T1D), autoimmune thyroiditis (AT), and idiopathic thrombocytopenic purpura (ITP)]. Cases were consecutively and prospectively identified at specialized centers across France (2008-2014) and individually matched by age and place of residence to referents recruited in general practice. Risk was computed using multivariate conditional logistic regression models adjusted for family history of ADs, living in France (north/south), co-medications and co-vaccinations.
RESULTS: With a total of 478 definite cases matched to 1869 referents, all ADs combined were negatively associated to HPV vaccination with an adjusted odds ratio of 0.58 (95% confidence interval: 0.41-0.83). Similar results were obtained for CD/MS, AT, CT, and T1D, the last two not reaching statistical significance. No association was found for ITP and GBS. Sensitivity analyses combining definite and possible cases with secondary time window showed similar results.
CONCLUSION: Exposure to HPV vaccines was not associated with an increased risk of ADs within the time period studied. Results were robust to case definitions and time windows of exposure. Continued active surveillance is needed to confirm this finding for individual ADs.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; HPV vaccine; Pharmacoepidemiology

Mesh:

Substances:

Year:  2017        PMID: 28190705     DOI: 10.1016/j.jaut.2017.01.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  20 in total

1.  Urban-Rural Inequities in the Parental Attitudes and Beliefs Towards Human Papillomavirus Infection, Cervical Cancer, and Human Papillomavirus Vaccine in Mysore, India.

Authors:  Abraham Degarege; Karl Krupp; Kristopher Fennie; Tan Li; Dionne P Stephens; Laura A V Marlow; Vijaya Srinivas; Anjali Arun; Purnima Madhivanan
Journal:  J Pediatr Adolesc Gynecol       Date:  2018-03-26       Impact factor: 1.814

Review 2.  Safety of Human Papillomavirus Vaccines: An Updated Review.

Authors:  Anastasia Phillips; Cyra Patel; Alexis Pillsbury; Julia Brotherton; Kristine Macartney
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

Review 3.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

4.  Thyroid Inconveniences With Vaccination Against SARS-CoV-2: The Size of the Matter. A Systematic Review.

Authors:  Verdiana Caironi; Fabián Pitoia; Pierpaolo Trimboli
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

Review 5.  Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society.

Authors:  Alexandru Barboi; Christopher H Gibbons; Felicia Axelrod; Eduardo E Benarroch; Italo Biaggioni; Mark W Chapleau; Gisela Chelimsky; Thomas Chelimsky; William P Cheshire; Victoria E Claydon; Roy Freeman; David S Goldstein; Michael J Joyner; Horacio Kaufmann; Phillip A Low; Lucy Norcliffe-Kaufmann; David Robertson; Cyndya A Shibao; Wolfgang Singer; Howard Snapper; Steven Vernino; Satish R Raj
Journal:  Clin Auton Res       Date:  2019-09-02       Impact factor: 4.435

6.  Variation in genes implicated in B-cell development and antibody production affects susceptibility to pemphigus.

Authors:  Verónica Calonga-Solís; Leonardo M Amorim; Ticiana D J Farias; Maria Luiza Petzl-Erler; Danielle Malheiros; Danillo G Augusto
Journal:  Immunology       Date:  2020-10-09       Impact factor: 7.397

7.  HPV vaccination of immunocompromised hosts.

Authors:  S M Garland; J M L Brotherton; A B Moscicki; A M Kaufmann; M Stanley; N Bhatla; R Sankaranarayanan; S de Sanjosé; J M Palefsky
Journal:  Papillomavirus Res       Date:  2017-06-03

8.  Reply to Poddighe.

Authors:  Louise Stevenson; L-M Huang; Valérie Berlaimont; Nicolas Folschweiller
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

9.  Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System.

Authors:  W Katherine Yih; Judith C Maro; Michael Nguyen; Meghan A Baker; Carolyn Balsbaugh; David V Cole; Inna Dashevsky; Adamma Mba-Jonas; Martin Kulldorff
Journal:  Am J Epidemiol       Date:  2018-06-01       Impact factor: 4.897

Review 10.  Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

Authors:  Marc Arbyn; Lan Xu; Cindy Simoens; Pierre Pl Martin-Hirsch
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.